Clover Biopharmaceuticals, Ltd.
三葉草生物製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2197)

VOLUNTARY ANNOUNCEMENT CLOVER PRESENTS UPDATED DURABILITY AND BOOSTER DATA FOR COVID-19 VACCINE CANDIDATE AT WORLD VACCINE CONGRESS WASHINGTON 2022

This announcement is made by the board (the "**Board**") of directors of Clover Biopharmaceuticals, Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest clinical development status of the core product of the Group.

The Company is pleased to announce additional positive data from two ongoing studies evaluating SCB-2019 (CpG 1018/Alum), which demonstrated durable protection through approximately six months following primary vaccination and robust immune responses in neutralizing Omicron and other variants of concern after a booster dose in an expanded data set involving over 100 participants. These data were announced as part of a larger presentation, *Clover's adjuvanted protein-based vaccine: efficacy against SARS-CoV-2 variants and duration of protection,* delivered on April 18, 2022 at the World Vaccine Congress Washington 2022.

Durability of Protection at Approximately Six Months Following Primary Vaccination Series

New datasets from an extended follow-up analysis confirm earlier findings and show that SCB-2019 (CpG 1018/Alum) elicited high and durable protection in individuals at approximately six months after the primary vaccination series. The follow-up analysis involved more than 14,700 individuals without evidence of SARS-CoV-2 exposure, and more than 14,700 subjects with evidence of prior SARS-CoV-2 exposure.

In adults (18-59 years of age) with no history of SARS-CoV-2 infection, efficacy against any SARS-CoV-2 strain was maintained at 100% for severe COVID-19 and 95% against hospitalizations due to COVID-19, at approximately 6 months after the primary vaccination series. In the elderly population (≥60 years of age), efficacy against any SARS-CoV-2 strain was maintained at 100% for severe COVID-19 and 100% against hospitalizations, at approximately six months after the primary vaccination series.

In individuals with prior SARS-CoV-2 infection, efficacy against any SARS-CoV-2 strain was 71% for any severity of COVID-19 after primary vaccination with SCB-2019 (CpG 1018/Alum) and no decline in clinical efficacy against COVID-19 was observed over the approximate six-month period. In this population, a rapid increase of neutralizing antibodies following the first dose of SCB-2019 (CpG 1018/Alum) was associated with clinical protection against COVID-19, which was maintained for approximately six months after the primary vaccination.

No safety concerns were observed in individuals dosed with SCB-2019 (CpG 1018/Alum) within the follow-up period. The Company will continue to analyze the data and report results as they become available.

Updated Heterologous Booster Data in an Expanded Data Set

- **Boosting data against the prototype strain:** A heterologous booster dose of SCB-2019 (CpG 1018/Alum) in individuals previously receiving two doses of AstraZeneca's COVID-19 vaccine elicited **approximately 4-fold higher** levels of neutralizing antibodies against the prototype strain when compared to individuals receiving three doses of AstraZeneca's vaccine. In this expanded population of 103 individuals, as compared to the initial data in 76 individuals announced in February 2022, SCB-2019 (CpG 1018/Alum) as a heterologous booster dose provided a strong recall response, demonstrating clear evidence of immune maturation.

- **Booster data against Omicron and other variants of concern:** A heterologous booster dose of SCB-2019 (CpG 1018/Alum) in individuals previously receiving two doses of AstraZeneca's COVID-19 vaccine elicited **approximately 3-fold higher** levels of neutralizing antibodies against the Omicron variant when compared to individuals receiving three doses of AstraZeneca's vaccine. In this expanded population of 120 individuals, as compared to the initial data in 79 individuals announced in March 2022, SCB-2019 (CpG 1018/Alum) showed a higher neutralizing antibody response against variants of concern, including Beta, Gamma, Delta and Omicron, in comparison to individuals receiving three doses of AstraZeneca's vaccine.

The Company expects to submit full findings from the studies to a peer-review publication in the near future.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately commercialize SCB-2019 (CpG 1018/Alum) successfully.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, April 19, 2022

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Mr. Ting XIAO and Mr. Dong LYU as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.